+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID03342144

Observational Study on Venetoclax Use in Chronic Lymphocytic Leukemia Patients Receiving Real-Life Treatments Across Austria, Germany, and Switzerland

Led by AbbVie · Updated on 2026-10-21

500

Participants Needed

74

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are observing participants with Chronic Lymphocytic Leukemia CLL who are receiving venetoclax either alone or combined with rituximab, obinutuzumab, ibrutinib, or acalabrutinib. The study aims to assess the effectiveness, health-related costs, and participant-reported outcomes in real-life clinical settings, reflecting typical medical practice. This observational study is sponsored by AbbVie and involves patients treated according to local clinical guidelines. Participants are grouped based on their treatment regimen, including venetoclax alone or with one of the specified combination therapies. Treatments are prescribed at the physicians discretion and according to local labels, without experimental intervention from the study. The study captures data as patients receive their usual care with these therapies. During the study, participants responses to treatment are monitored, focusing on the best overall response rate within 12 months. Researchers collect health economic data and patient-reported outcomes to understand the impact of these treatment approaches in everyday practice. Participation involves observation and data collection without altering prescribed therapies, continuing until the study completion in December 2030.

CONDITIONS

Brief Title

Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting

Research Team

J

Johannes Huelsenbeck

S

Stefan Lorenz

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here